Oculis to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Oculis (Nasdaq: OCS) announced management participation in multiple investor conferences in November 2025, including Guggenheim (Nov 10-12), Stifel (Nov 11-13), LifeSci Capital & Sofinnova (Nov 17) and ICR Healthcare (Nov 17).

Key program items: Privosegtor advanced into registrational trials for acute optic neuritis and NAION after a positive FDA meeting; OCS-01 topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab PREDICT-1 registrational trial in DED anticipated soon as a genotype-based program. CEO Riad Sherif will give fireside chats on Nov 11 (2:30 pm ET) and Nov 12 (2:00 pm ET); management will be available for one-on-one meetings and webcasts will be posted to the Events & Presentation page.

ZUG, Switzerland, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced today that Oculis’ management will participate in upcoming investor conferences in November.

Oculis is pleased to present updates of its innovative, highly differentiated, late-stage portfolio as it enters a pivotal phase in its transformation into a leader in neuro-ophthalmology and ophthalmology. Key highlights include: Privosegtor (PIONEER program) advancement into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION), following a positive FDA meeting; OCS-01 (DIAMOND registrational trials) topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab (PREDICT-1 registrational trial) in DED anticipated soon, marking the first genotype-based development program to drive precision medicine.

With a strong balance sheet and robust pipeline, Oculis is well-positioned to deliver 6 pivotal readouts with the current funding, to fulfil its mission to save sight and improve eye care with groundbreaking treatments.

Guggenheim Securities 2nd Annual Healthcare Innovation Conference
November 10-12; Boston, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 11^th at 2:30 pm ET.
Webcast link: Register here.

Stifel Healthcare Conference
November 11-13; New York, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, on November 12^th at 2:00 pm ET.
Webcast link: Register here.

LifeSci Capital and Sofinnova Partners Growth & Innovation Summit
November 17; London, U.K.
Oculis management will participate in one-to-one meetings.

ICR Healthcare and Sponsors 13th Annual Healthcare Conference
November 17; London, U.K.
Riad Sherif, M.D., Chief Executive Officer, will participate in a panel discussion, entitled ‘Brave New World,’ at 1:50 pm GMT.

The company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNFα in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the development plans for Privosegtor, OCS-01, and Licaminlimab; the initiation, timing, progress and results of clinical trials of Privosegtor, OCS-01, and Licaminlimab; and Oculis’ research and development programs, regulatory and business strategy, future development plans, and management, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

FAQ

When will Oculis present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference (OCS)?

Oculis management will participate Nov 10–12, 2025, with a fireside chat by CEO Riad Sherif on Nov 11 at 2:30 pm ET.

What time is the Oculis (OCS) fireside chat at the Stifel Healthcare Conference?

The CEO fireside chat is scheduled for Nov 12, 2025 at 2:00 pm ET.

Which late‑stage Oculis programs will be discussed at the November 2025 investor events (OCS)?

Management will highlight Privosegtor (registrational trials for acute optic neuritis and NAION), OCS-01 (DIAMOND registrational trials) and Licaminlimab (PREDICT-1 for DED).

When does Oculis expect topline results for OCS-01 diabetic macular edema (OCS)?

Topline results for OCS-01 in diabetic macular edema are expected in Q2 2026.

How can investors request one‑on‑one meetings with Oculis management (OCS) at the conferences?

Interested investors should contact their representative at the sponsoring institution to request meetings; webcast links and event details will be posted on Oculis' Events & Presentation investor page.

What recent regulatory milestone will Oculis (OCS) discuss related to Privosegtor?

Oculis will note that Privosegtor advanced into registrational trials for acute optic neuritis and NAION following a positive FDA meeting.